Neal Meropol

[Neal Meropol @NealMeropol]

@IvyLorena_Md @CamilaBragancaX @AACR @ASCO @AHerrmannMD @DartmouthCancer @ASCOTECAG @jacobadashek @HemOncFellows @ClevelandClinic There’s nothing quite like the @AACR @ASCO clinical trials workshop! What a great week spent with the future leaders in clinical research!

[Neal Meropol @NealMeropol]

Clinical trials need to be representative if we expect the results to be applicable to ALL cancer patients. Let's double down to help address this imperative by carefully designing trials that optimize patient access!

[Flatiron Health @flatironhealth]

“It’s really a crisis. And it’s a societal imperative, in my opinion, to fix this problem of #clinicaltrial representativeness.”

Building off an article in @NEJMEvidence, data has the ability to transform trials, improve outcomes, & address disparities.

https://t.co/5fAMpAqgR7

[Neal Meropol @NealMeropol]

Many thanks to Daniel Levine on The Bio Report for a great conversation about the many ways that #realworlddata can support evidence generation to benefit cancer patients.

[Flatiron Health @flatironhealth]

Neal Meropol, Head of Research Oncology, was recently interviewed on The Bio Report podcast to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development.

Tune in: https://t.co/GYv4S4lJsW

[Flatiron Health @flatironhealth]

Neal Meropol, Head of Research Oncology, was recently interviewed on The Bio Report podcast to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development.

Tune in: https://t.co/GYv4S4lJsW

[Neal Meropol @NealMeropol]

@flatironhealth @NCCN The @flatironhealth<> @NCCN collaboration is a great example of how public-private partnerships can accomplish the shared goal of advancing cancer research and care!

[Flatiron Health @flatironhealth]

ANNOUNCED TODAY: Flatiron is expanding their collaboration with @NCCN to further enable research with #RWD, create meaningful impact on cancer care, & allow cancer centers access to data sets to evaluate & enhance the quality of care given at their sites.
https://t.co/ER0kad9kOL

[Neal Meropol @NealMeropol]

@flatironhealth @NEJMEvidence I am so excited to see this work come to fruition! Our new findings demonstrate that loosening common eligibility criteria can disproportionately benefit patient populations who are historically underrepresented in clinical trials. https://t.co/2FdSrExYvq

[Flatiron Health @flatironhealth]

#NewResearch published today in @NEJMEvidence, investigates how #RWD use to optimize and broaden inclusion criteria impacts the diversity of eligible patients with cancer.

Hear from Maneet Kaur about the study's inspiration and explore the full pub: https://t.co/jesMNhJmtQ

[Neal Meropol @NealMeropol]

@flatironhealth @HL7 Congrats Matt!

[Neal Meropol @NealMeropol]

@flatironhealth @FierceBiotech The clinical trials ecosystem has lagged behind other industries in leveraging technological advancements -- if we embrace the possible, we can make clinical trials more accessible to patients and more efficient for study sites and sponsors.

[Flatiron Health @flatironhealth]

#Clinicalresearch data collection & transfer methods have not significantly advanced over the last 50 years.

A new paper by @flatironhealth & @FierceBiotech proposes ways that the EHR can accelerate #clinicaltrials to benefit patients, sites, & sponsors https://t.co/ErDCrB9uRa

[Neal Meropol @NealMeropol]

Moving clinical trial data collection into the 21st century.

[Flatiron Health @flatironhealth]

Technology has the power to support changes needed to reduce #clinicalresearch site burden, especially related to data collection. https://t.co/Uk8LZO0yO7

Connect with our team to discuss how our EHR-to-EDC tech is changing the future of clinical research https://t.co/UkeNfjBJWq

[Neal Meropol @NealMeropol]

@RueschCenter @flatironhealth @LombardiCancer @MedStarGUH @OncLive @gumedcenter @Georgetown_HIDS @MarionHartley4 @clustinthewind @benweinbergmd @GICAlliance @RuthHe12 @ReetuMukherjiMD @AliAlqahtaniMD Much gratitude to @LombardiCancer @RueschCenter and Schafer family for helping to end suffering from GI cancers

[Cure GI Cancers @RueschCenter]

Register today for the #RueschSymposium keynote with @NealMeropol of @flatironhealth on Friday, November 18th at 12PM ET. Join us in person or virtually using promo code Guest2022. https://t.co/cflynvxmE1.

@LombardiCancer @MedStarGUH @OncLive

[Neal Meropol @NealMeropol]

@flatironhealth @TheCancerLetter @theNCI Hoping we can begin to move the needle!

[Flatiron Health @flatironhealth]

@FlatironHealth’s @NealMeropol spoke w/@TheCancerLetter on @theNCI CTAC proposed guidelines for streamlining data collection requirements for clinical trials.

Neal, Co-Chair of the NCI’s Working Group on Streamlining Clinical Trials, shared his thoughts:
https://t.co/ANsLvVL0Pp

[Cure GI Cancers @RueschCenter]

Join leading GI Cancer experts at the 13th Annual Ruesch Center Symposium on November 18th and 19th. Learn more about the agenda and speakers for Friday, November 18th. Use promo code Guest2022 to register. https://t.co/cflynvxUtz
@LombardiCancer @MedStarGUH

[Neal Meropol @NealMeropol]

@DrSGraff Chock full of important insights!

[Neal Meropol @NealMeropol]

@DrSGraff Chock full of important insights!

[Flatiron Health @flatironhealth]

Ariel Bourla sat down w/ @JournPrecMed to discuss a study done in partnership w/@FoundationATCG & @Genentech, that found potential for an add'l diagnostic approach to personalized NSCLC therapy. More on the thought & design behind this innovative study. https://t.co/rXtYMSyixr